TScan Therapeutics (TCRX) said Thursday that it signed a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for the sale of about $30 million of pre-funded warrants.
Under the terms of the deal, the warrants allow Lynx1 to purchase up to 7.5 million shares of TScan's voting common stock for $4 per pre-funded warrant, representing a premium of 37% to the last closing price of TScan's common stock and a 34% premium over the 10-day volume weighted average closing price, according to TScan.
The financing is expected to close Friday, the company added.
Shares of TScan jumped more than 20% in recent premarket activity Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。